Monitor for selling by RA Capital once the registration becomes effective. The out-of-the-money common stock warrants ($10 strike) limit immediate conversion risk, but the pre-funded warrants are essentially exercisable now. Watch for any filing of a 13D amendment or block trades from RA Capital.
KPTI drugs
KPTI drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 5 $9.41entry
- T+1 · 7mo ago 0.00%α −1.38% · $9.41
- T+5 · 6mo ago −6.38%α −8.36% · $8.81
- T+20 · 6mo ago −1.91%α −6.87% · $9.23
- T+60 · 4mo ago −25.50%α −28.24% · $7.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Karyopharm filed an S-3 shelf registration for the resale of up to 8,843,036 shares by RA Capital Healthcare Fund, consisting of 1,030,354 outstanding shares, 3,391,164 pre-funded warrant shares, and 4,421,518 common stock warrant shares. The company will receive no proceeds from this resale; the filing fulfills registration rights granted in the March 2026 private placement that raised $30M. The common stock warrants have a $10 exercise price (currently out of the money at $8.40), so near-term selling is likely limited to the already-issued shares.
Key Facts
- Registration covers 1,030,354 outstanding shares, 3,391,164 pre-funded warrant shares (exercise $0.0001), and 4,421,518 common stock warrant shares (exercise $10.00).
- Company receives no proceeds from resale; gross proceeds from original March 2026 private placement were $30M.
- Common stock warrants are out of the money (exercise $10 vs. current $8.40).
- RA Capital is currently limited to beneficial ownership of 9.99% (2,290,108 shares) but may increase that limit upon 61 days' notice.
Financial Impact
No new capital raised; registered shares represent ~39% of current shares outstanding (22.55M), creating potential overhang but no immediate dilution from new issuance.
Risk Factors
- Potential selling pressure from RA Capital's resale of the 1.03M outstanding shares and pre-funded warrant shares.
- Further dilution if the common stock warrants are exercised (requires stock price above $10).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-204134 |
| Document: d81858dex41.htm | 0001193125-26-204134 |
| Document: d81858dex44.htm | 0001193125-26-204134 |
Track record
30 reports on KPTI
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers